2 completed, 1 terminated, 1 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow GPI-0100: new trials by email Literature Review of GPI-0100 trials Research Report on GPI-0100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma | Phase 2 | Terminated | Endocyte | 12 | 2007-06-01 | 2012-03-08 |
| Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Cancer | Phase 1 | Completed | Endocyte | 13 | 2005-09-01 | 2012-03-09 |
| Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer GPI-0100, MUC-2-Globo H-KLH conjugate vaccine - Prostate Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 34 | 2000-07-01 | 2013-03-19 |
Neoplasms (2) · Carcinoma, Renal Cell (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Recurrence (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1)
Endocyte (2) · Memorial Sloan Kettering Cancer Center (1) · THEVAX Genetics Vaccine (1)
United States (4)
Richard A Messmann, MD, MHS, BSc (2) · Frank L Douglas, PhD, MD (1) · Susan Slovin, MD, PhD (1)
P30CA008748 (1)